Twist Bioscience TWST Jumps As Guidance, Targets And Cash Raise Align
Twist Bioscience (TWST) shares rose about 7.9% after Q3 results and guidance. Q3 revenue was $118.4M vs ~$114.5M consensus, with EPS loss widening to ($0.56). Full-year 2026 revenue guidance rose to $456M-$457M and Q4 revenue to $123M-$124M, targeting adjusted EBITDA breakeven. The company priced a $300M offering at $96.
How this was made
The 30-second read
Why it matters
Guidance increases for both Q4 and FY2026, plus a stated adjusted EBITDA breakeven target, are the core bullish drivers. The upsized $300M equity offering at $96 is the key near-term bearish offset via dilution and potential supply overhang.
Market read
This is a company-specific beat-and-raise plus capital raise story, which typically drives momentum trading and re-rating in growth biotech.
What to watch
EPS loss widened to ($0.56) and EBIT margin remains deeply negative, so the market may be underpricing the risk that profitability progress lags revenue growth.
Background
The article frames TWST as a high-growth biotech with strong gross margin and improving cash-generation expectations, but still negative earnings.
Ticker impact
Twist Bioscience raised FY2026 revenue guidance to $456M-$457M, guided Q4 revenue to $123M-$124M, and priced a $300M offering at $96.
Likely continued upside bias while traders focus on guidance and breakeven timing, with pullbacks possible around offering-related supply and any margin/growth miss.
The article provides multiple fresh, company-specific catalysts (guidance raise, Q4 revenue range, EBITDA breakeven target, and a newly priced upsized equity offering). The main counterweight is dilution, which can cap rallies and increase volatility.
Market effects
Reinforces the biotech growth trade where strong unit economics (high gross margin) plus AI-enabled demand can offset ongoing losses.
No specific regional spillover described beyond US small/mid-cap biotech momentum.
No explicit global catalyst beyond general AI drug-discovery demand framing.
Counterpoint
The stock’s move may be overly optimistic if adjusted EBITDA breakeven depends on execution that could slip, while the $96 offering can pressure the tape through dilution.
Key entities
- companyTwist Bioscience Corporation
Reported Q3 revenue beat, raised FY2026 and Q4 revenue guidance, targeted adjusted EBITDA breakeven, and priced an upsized $300M equity offering at $96.
